Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer.

Reshma Mahtani; V. Gadi; T. Operna; H. Soifer; B. Schroeder; C. Schnabel; L. Schwartzberg

Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer.

Reshma Mahtani, V. Gadi, T. Operna, H. Soifer, B. Schroeder, C. Schnabel, L. Schwartzberg

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting
Volume	35
State	Published - 2017

Disciplines

Medicine and Health Sciences

Cite this

Mahtani, R., Gadi, V., Operna, T., Soifer, H., Schroeder, B., Schnabel, C., & Schwartzberg, L. (2017). Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer. Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting, 35.

Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer. / Mahtani, Reshma; Gadi, V.; Operna, T. et al.
In: Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting, Vol. 35, 2017.

Research output: Contribution to journal › Article › peer-review

Mahtani, R, Gadi, V, Operna, T, Soifer, H, Schroeder, B, Schnabel, C & Schwartzberg, L 2017, 'Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer.', Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting, vol. 35.

@article{4b1a206340194dc58992ba9e9cb7aa17,

title = "Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer.",

author = "Reshma Mahtani and V. Gadi and T. Operna and H. Soifer and B. Schroeder and C. Schnabel and L. Schwartzberg",

note = "551 Background: Randomized trials demonstrated a modest (3-5\%) absolute benefit from EET in patients (pts) with early stage HR+ breast cancer (BC), but also a risk of toxicities.",

year = "2017",

language = "American English",

volume = "35",

journal = "Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting",

}

TY - JOUR

T1 - Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer.

AU - Mahtani, Reshma

AU - Gadi, V.

AU - Operna, T.

AU - Soifer, H.

AU - Schroeder, B.

AU - Schnabel, C.

AU - Schwartzberg, L.

N1 - 551 Background: Randomized trials demonstrated a modest (3-5%) absolute benefit from EET in patients (pts) with early stage HR+ breast cancer (BC), but also a risk of toxicities.

PY - 2017

Y1 - 2017

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.551

M3 - Article

VL - 35

JO - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting

JF - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting

ER -

Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer.

Disciplines

Other files and links

Cite this